Genetics in the endocrine system: the impact of the TRK family

Rearrangements in NTRK are rare actionable oncologic drivers in thyroid carcinoma. Although they only represent a small subset of most thyroid carcinoma subtypes, their identification remains important due to the availability of targeted therapy. Trk inhibitors are currently FDA-approved for NTRK-rearranged cancers independent of primary site and represent a crucial additional therapeutic option for patients with advanced or aggressive thyroid cancer. In the thyroid, NTRK-rearranged cancers have been shown to involve all NTRK family members (NTRK1, NTRK2, and NTRK3) as well as a multitude of different partner genes.
Source: Diagnostic Histopathology - Category: Pathology Authors: Tags: Mini-symposium: endocrine pathology: single-gene impacts Source Type: research